Research programme: biotherapeutics - Gene Techno Science

Drug Profile

Research programme: biotherapeutics - Gene Techno Science

Alternative Names: GBS-002; GBS-003; GBS-006; GBS-009; GND-001; GND-002; GND-003; GND-004; GND-005

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gene Techno Science
  • Class Antibodies
  • Mechanism of Action Immunomodulators; Integrin alpha9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Immunological disorders
  • Discontinued Cardiovascular disorders

Most Recent Events

  • 16 Nov 2017 Preclinical development in Cancer and Immunological disorders is ongoing Japan (Gene Techno Science pipeline, November 2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top